A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642).

K C Shih,H A Burris,A Nasir,D Farrington,J Leohr,A W Tolcher,J R Infante,J T Brandt,A Patnaik,J C Bendell,A Mcglothlin,E H Westin,L Jackson,R Arcos,K P Papadopoulos,M Beeram,S Hynes

doi:10.1200/jco.2011.29.15_suppl.2600

A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642).

K C Shih, H A Burris + Show 15 more

https://doi.org/10.1200/jco.2011.29.15_suppl.2600

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2011
Citations: 3

#Eg5 Inhibitor #Bipolar Spindle Formation + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

2600 Background: LY2523355 is an allosteric inhibitor of Eg5 which selectively inhibits bipolar mitotic spindle formation. The objective of this Phase 1 study is to determine the Phase 2 dose and s...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.